Articles tagged with Alzheimer Disease
Researchers identified tau, a brain protein, as a potential target for stroke therapies. Mice deficient in tau showed significant protection from excitotoxic brain damage after experimental stroke, offering new avenues for treatment development.
Researchers at Lancaster University developed a novel blood test to diagnose Alzheimer's disease with high accuracy. The test distinguishes between Alzheimer's and other neurodegenerative diseases, reducing misdiagnosis cases.
Researchers have discovered anomalies in the slow wave activity of mice with cognitive decline similar to Alzheimer's, which may provide new insights into the disease. The study suggests that restoring these waves could potentially be a therapeutic approach.
Researchers at Lund University have developed an imaging method that shows changes in the brain associated with Alzheimer's disease at different stages of life. The method uses a PET camera and a trace substance to detect tau protein and can facilitate diagnosis and treatment for younger patients.
Researchers have discovered that stabilizing TREM2, a protein involved in neurodegenerative diseases, could be a viable therapeutic strategy to combat Alzheimer's disease. The study found that a mutation in the TREM2 gene accelerates its cleavage, leading to reduced full-length protein on microglia cells.
A decline in navigational skills could be an early sign of Alzheimer's disease, according to researchers. Researchers are exploring the possibility of using navigational impairments as a diagnostic tool for neurodegenerative diseases.
Researchers have designed a new kind of antibody that targets toxic protein structures common to Alzheimer's disease, Parkinson's disease, and related conditions. The study demonstrates the effectiveness of these antibodies in removing toxic forms without triggering immune toxicity.
Researchers at UNC School of Medicine have discovered a damaging cascade of events inside brain cells that contribute to Alzheimer's disease. The study shows that amyloid beta protein can trigger an inflammatory response in immune cells, leading to the formation of bead-like structures filled with abnormal tau protein.
A new study published in JAMA Neurology analyzed 27 research studies and found that female carriers of the apolipoprotein E ?4 allele have a greater risk of developing Alzheimer disease, particularly between ages 65-75. The authors suggest physiologic changes associated with menopause and estrogen loss may underlie these sex differences.
A study by USC researchers found that white women with a genetic predisposition to Alzheimer's are more likely to develop the disease during a critical decade in their lives. The study, which included data from over 57,000 participants, contradicts long-held beliefs about who is at greatest risk for Alzheimer's.
A team of seven University of Maryland undergraduates developed a portable electroencephalogram (EEG) device that uses audio tones to detect Alzheimer's disease before symptoms appear. The device exploits changes in brainwaves, allowing for early diagnosis and treatment, potentially saving billions in healthcare costs.
Researchers review neuroinflammation as a key factor in Alzheimer's and Parkinson's diseases, highlighting four modifiable risk factors: physical inactivity, vascular disease-related conditions, obesity, and type two diabetes mellitus. Controlling these risk factors may help manage the increasing incidence of both diseases.
The Boston University Alzheimer's Disease Center has received a three-year grant from the NIH to advance research on Alzheimer's disease. The center aims to develop tests for early diagnosis and interventions to prevent or delay the disease.
Researchers at Arizona State University have developed an early blood test for Alzheimer's disease that can detect the disease before symptoms appear. The test distinguishes between Alzheimer's, Parkinson's, and healthy controls by analyzing RNA transcripts in white blood cells.
A study published in Neurology found that less REM sleep and longer sleep latency are associated with a higher risk of developing dementia. Research followed 321 participants over 12 years, revealing a nine percent increase in all-cause dementia risk for each percentage reduction in REM sleep.
Researchers at Cedars-Sinai and NeuroVision LLC have developed an experimental optical imaging system that detects retinal beta-amyloid, a hallmark of Alzheimer's disease. The study found a 4.7-fold increase in retinal plaque burden in patients with Alzheimer's compared to controls.
A study adapts a noninvasive retinal imaging approach to detect and quantify amyloid-β plaques in AD patients and healthy controls, revealing increased deposits in AD patients. This technology has the potential to enable significant advances in early detection and treatment of Alzheimer's disease.
Researchers developed a noninvasive eye scan to detect Alzheimer's disease years before symptoms appear, revealing amyloid-beta deposits and toxic proteins in the retina. The findings offer new hope for early detection and disease monitoring, with the potential to intervene and change the course of the disorder.
Researchers found that individuals with difficulty identifying odors had elevated AD-related proteins in their cerebrospinal fluid. The study suggests a potential cheaper alternative for tracking the progression of Alzheimer's disease through simple smell tests.
A new machine learning program developed by researchers at Case Western Reserve University appears to outperform other methods for diagnosing Alzheimer's disease before symptoms begin. The program integrates various indicators of the disease, including mild cognitive impairment, to predict who has Alzheimer's and those with mild cognit...
A Johns Hopkins study found that individuals with mild cognitive decline have lower levels of serotonin transporters, suggesting a possible driver of the disease. The research suggests increasing serotonin function may prevent memory loss and slow disease progression.
Researchers found that brain-stimulating activities, physical activity, and a healthy lifestyle can reduce AD risk by up to 65 percent. Addressing known risk factors such as diabetes, high blood pressure, and depression can also prevent up to 30 percent of AD cases.
Researchers at MIT have found a way to precisely target the enzyme HDAC2, which blocks genes required for memory formation in Alzheimer's patients. By blocking its interaction with Sp3, they were able to reverse memory loss in mice, offering a potential new treatment approach.
A study found that a single injection of the longevity hormone klotho fragment improved spatial and working memory, strengthened neuron connections, and countered cognitive deficits in mice. The treatment lasted for several weeks and showed promise as a potential therapy for neurodegenerative diseases.
Aged chimpanzee brains exhibit pathology similar to human Alzheimer's disease, including Aβ plaques and tau lesions. The study provides the most extensive evidence of AD brain pathology in a primate species, shedding light on the evolution and potential targets for therapeutic interventions.
Researchers found that impaired lysosome transport contributes to protein aggregate buildup in brains of mice with Alzheimer's. Developing ways to restore lysosome transport could represent a new therapeutic approach.
Researchers discovered that older adults with a diagnosis of Mild Cognitive Impairment or mild stage Alzheimer's disease dementia reported lower quality of life compared to those without a diagnosis. The study also found that awareness of worsening prognosis had a negative impact on daily life satisfaction.
Researchers at the University Medical Center Goettingen identified a molecular link between PTSD and Alzheimer's disease, specifically Formin 2. Formin 2 mutant mice show PTSD phenotypes at an early age and develop age-related memory decline.
Researchers from Kent State University have identified pathologic hallmarks of Alzheimer's disease in the brains of aged chimpanzees, similar to human Alzheimer's disease brain pathology. The study found amyloid beta plaques and blood vessels in all 20 aged chimpanzee brains, with increasing sizes correlating to age.
A new BACE inhibitor has shown promise in improving brain function and memory performance in a mouse model of Alzheimer's disease. The study found that the treatment reduced amyloid beta production, restored normal nerve cell function, and improved memory abilities.
Researchers developed a multilayer clustering algorithm to sort through dozens of data points from two large studies, identifying two distinct groups: rapid decliners and slow-moving disease. The 'rapid decliners' group showed twice the rate of brain atrophy and progressed faster to dementia.
Researchers at Ohio State University have identified new physical biomarkers that can help confirm a diagnosis and predict disease progression. The study uses changes in proteins found in spinal fluid and blood to rate the severity of illness, identifying stages and progression with increased reliability.
Researchers have discovered molecular basis of hereditary Alzheimer's disease, revealing a crucial role in the cleavage process of APP protein. Stabilizing Gamma Secretase-APP interaction may prevent release of toxic amyloid beta fragments, delaying or preventing the disease.
Researchers developed a new, non-invasive method called transcranial magnetic stimulation (TMS) to distinguish between Alzheimer's disease and frontotemporal dementia. The technique accurately diagnosed the conditions with 90% accuracy in most cases.
Researchers have identified a new way for brain cells to become fated to die during Alzheimer's disease, linked to the activation of a biological pathway called necroptosis. The study found that necroptosis is closely linked with Alzheimer's severity, cognitive decline and extreme loss of tissue and brain weight.
Research suggests that sleep disorders are associated with diminished cognition in individuals carrying a genetic susceptibility to Alzheimer's disease. Specifically, APOE-ε4 carriers showed greater cognitive deficits with various indices of sleep-disordered breathing compared to those without the allele. The study found increased over...
Researchers at the University of British Columbia have found that changing where an enzyme cuts a protein precursor can reduce amyloid beta plaque buildup, a key factor in Alzheimer's disease. By guiding the enzyme to a different point, the researchers may be able to achieve the same goal with less collateral damage.
Researchers have developed a blood test that can detect amyloid beta plaques in the brain, a key characteristic of Alzheimer's disease. The test measures levels of three different amyloid subtypes and has been shown to be highly accurate in identifying individuals with altered levels of amyloid in their brains.
Researchers at LSU Health New Orleans found that docosahexaenoic acid (DHA) and its bioactive derivative NPD1 can reduce stroke damage and promote cell survival in the brain. DHA is essential for maintaining cellular homeostasis, which is disrupted in diseases such as Alzheimer's and Parkinson's.
According to a revised pipeline analysis, six Alzheimer's drugs will conclude Phase III trials in 2017, bringing much-needed solutions to families in the near future. The late-stage pipeline offers hope to 5.5 million Americans with the disease and their caregivers.
Researchers have discovered increased bacterial populations and specific bacteria differences in Alzheimer's brains compared to healthy brains. The findings suggest that bacterial infection and inflammation could play a role in the disease.
Researchers have developed a simple methodology to capture proteins implicated in Alzheimer's disease and other conditions. The new method uses engineered tails to trap sugar-modified proteins, which can then be identified using routine laboratory techniques.
A study of 930 older adults found that non-elective hospitalizations accelerated cognitive decline by 60%, while elective hospitalizations had no association. Researchers highlight the need for attention on hospitalization as a risk factor for dementia and cognitive decline in older adults.
A study of 85,000 subjects identified three new gene variants that contribute to the development of Alzheimer's disease by affecting the brain's immune cells. Researchers believe these findings offer fresh ideas for targeting the immune system to fight the disorder.
Researchers at Cardiff University have discovered two new genes that increase a person's risk of developing Alzheimer's disease. The findings build on previous research identifying 24 susceptibility genes and provide insights into the mechanisms underlying the disease.
Researchers have found that inhibiting cell receptors can clear toxic protein buildup, reduce brain inflammation, and improve cognitive performance in animal models of Parkinson's and Alzheimer's diseases. The study also suggests that this inhibition may help insulate the brain from circulating inflammatory cells.
A large-scale trial found that person-centered activities combined with one hour of social interaction per week can improve the lives of people with dementia in care homes. The approach also saves money compared to standard care.
A randomized trial found that combining a specific care management program with memantine significantly improves daily function in Alzheimer's patients. The study shows that the medication plus care program patient group tested 7.5 times higher than the medication-only group.
Researchers have identified altered ANK1 gene expression in microglia cells of individuals with Alzheimer's disease, which is associated with neuroinflammation. The study found that increased ANK1 expression in microglia may be a response to neurodegeneration and neuroinflammation.
Researchers will use PET scans and MRI to detect harmful chemical build-up and measure brain structure, with a focus on 40-65 year olds. The project hopes to develop ways to intervene before irreversible damage is done.
Scientists at Lomonosov Moscow State University have identified a peptide complex formed in the brain during early stages of Alzheimer's disease. The complex, stabilized by zinc ions, can be targeted by new compounds to block disease progression.
A study found that disrupting one night of sleep in healthy adults causes an increase in amyloid beta, a brain protein associated with Alzheimer's disease. A week of poor sleep also leads to an increase in tau protein, which has been linked to brain damage in Alzheimer's and other neurological diseases.
A new study examined the relationship between traumatic brain injury (TBI) and age-related cognitive change, finding no significant difference between participants with TBI and those without. The researchers suggest that future studies should collect more information on past TBIs to better understand their impact on cognitive decline.
A recent study published in Neurology suggests that people with normal thinking and memory skills but poor sleep quality may be at higher risk of developing Alzheimer's disease. Researchers found a link between sleep disturbances and biological markers for Alzheimer's disease in spinal fluid, including amyloid plaques and tau tangles.
Researchers found that the AEP enzyme trims alpha-synuclein into toxic pieces, similar to its effect on tau in Alzheimer's disease. This discovery offers a potential drug target for Parkinson's disease.
Research reveals a link between Alzheimer's and lower lung cancer risk due to mitochondrial dysfunction and chronic inflammation. A study analyzing over 1000 patient samples identified altered genes and confirmed the protective effect of Alzheimer's against lung cancer.
Research suggests that dysfunctional microglia cells can induce neurodegeneration in Alzheimer's by increasing phagocytosis of β-amyloid peptides, leading to synapse loss. This study provides new insights into the role of microglia cells in neurodegenerative diseases.
Researchers at USC found that stiff brain vessels and decreased blood flow are associated with the build-up of harmful plaque and cognitive decline. The study used patient data from the Alzheimer's Disease Neuroimaging Initiative to explore cerebrovascular resistance, a new way to calculate it, and its link to dementia.
Scientists used an evolutionary medicine approach to estimate Alzheimer's disease causative genes by focusing on ohnologs, duplicated genes vulnerable to change in number. The study successfully identified a group of genes related to the nervous system and high brain expression levels similar to known AD-causative genes.
Researchers identified a network of genes expressed in myeloid cells that contribute to Alzheimer's disease pathogenesis. A protein called PU.1 regulates this gene network, which may hold promise for therapeutic targets.